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Abstract
Background: We have developed an oligonucleotide microarray (genosensor) utilizing a double tandem
hybridization technique to search for 9 point mutations located in the most frequently altered codons of
the  TP53  gene. Isolated and multiplexed PCR products, 108 and 92 bp long, from exons 7 and 8,
respectively, were obtained from 24 different samples. Single-stranded target DNA was then prepared
from isolated or multiplexed PCR products, through cyclic DNA synthesis. Independent ssDNA's were
annealed with the corresponding pairs of labeled stacking oligonucleotides to create partially duplex DNA
having a 7-nt gap, which contains the sequence that will be interrogated by the capture probes forming
double tandem hybridization. In the case of multiplexed ssPCR products, only two stacking
oligonucleotides were added per target, therefore the gap for the PCR products having two consecutive
codons to be interrogated in exon 7 was 12 nt long, so only single tandem hybridization was produced
with these respective probes.
Results: 18 codon substitutions were found by DNA sequencing. In 13 of them a perfect correlation with
the pattern of hybridization was seen (In 5 no signal was seen with the wt probe while a new signal was
seen with the appropriate mutant probe, and in 8 more, as expected, no signal was seen with any probe
due to the absence of the corresponding probe in the array). In 3 other cases a mutation was falsely
suggested by the combination of the absence of the wild type signal along with a false signal in the other
probe. In the other 2 cases the presence of the mutation was not detected due to the production of a false
hybridization signal with the wild type probe. In both cases (false mutation or no mutation detected)
relatively stable mismatched target/probe duplexes should be formed. These problems could be avoided
by the addition of probes to improve the performance of the array.
Conclusion: Our results demonstrate that a simple TP53 microarray employing short (7-mer) probes,
used in combination with single or double tandem hybridization approach and a simple or multiplex target
preparation method, can identify common TP53 missense mutations from a variety of DNA sources with
good specificity.
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Background
Cancer is a group of diseases characterized by uncon-
trolled cell growth. According to The World Cancer
Report, cancer rates could further increase by 50% to 15
million new cases in the year 2020 [1]. The chances of sur-
viving the onset of some common cancers depend largely
on how early they are detected in addition to how well
they are treated.
The progression of mammalian cells towards malignancy
is an evolutionary process that involves an accumulation
of mutations at the molecular and chromosomal level. A
candidate for involvement in this process is the tumor
suppressor gene TP53 (MIM # 191170) which encodes a
transcription factor (p53 protein) with cancer inhibiting
properties. This gene is the most frequently mutated gene
in human cancer. Between 30% and 70% of cancers of
almost every organ and histological subtype have a point
mutation in one of the two TP53 gene copies together
with loss of the other copy [2-4]. In many cancers the dis-
tribution of mutations along the TP53 gene is tumor-spe-
cific, clustered between exons 5, 7 and 8. This region is
highly conserved throughout evolution [3]. In this
domain, six mutational "hotspots" have been identified at
codons 175, 245, 248, 249, 273, and 282. The mutational
profile of the TP53 gene is different between cancers, for
example, codons 157, 158, 248, 249, and 273 have been
designated as TP53 mutational hotspots in lung cancer
[5,6], while in breast cancer the mutational hotspots are
in codons, 175, 245, 248, 249 and 273 [7]. On the con-
trary, in cervical cancer the frequency of the p53 muta-
tions is very low. [8].
Because mutations in the TP53 gene are so common in
human tumors and have been widely reported in the liter-
ature, extensive mutational databases exist, such as that
maintained by IARC [9]. Walker et al. [10], have utilized
the IARC TP53 mutation database to define 73 "hotspots"
for mutation in TP53 related to changes in protein struc-
ture and function. Martin et al. [11] performed a system-
atic automated analysis of the effects of TP53 mutations
on the structure of the core domain of the p53 protein to
functionally classify the various types of p53 mutants
according to predicted effects on protein folding or DNA-
protein interactions. Most mutations are currently identi-
fied by conventional methods of polymorphism detection
and DNA sequencing [12]. A growing number of nucleic
acid hybridization techniques have recently been applied
to biomedical problems, including development of DNA
probe arrays for detection of TP53 mutations [13-15]. In
many applications, DNA chips containing surface-bound
oligonucleotides (probes) are used to interrogate sample
(target) sequence information through complementary
recognition (hybridization) in a highly parallel fashion
[16]. Major applications of DNA microarrays include gene
expression profiling [17,18] and gene mutation analysis
[19,20]. These techniques allow parallel analysis of multi-
ple DNA samples. Mutation studies with DNA microar-
rays are still at an early stage and are in continuous
development [21,22]. Although the field of microarray
assays is still in a relatively early stage, it is generally antic-
ipated that microarray assays will offer decreased cost and
faster results, compared with the traditional, more labor
intensive dideoxy sequencing approach. We recently
reported a novel tandem hybridization strategy and its
application for identification of mutations. Reliable dis-
crimination of point mutations has been achieved by
double tandem hybridization with a set of seven-mer
probes [23,24]. In the present work we designed a novel
small format DNA chip (genosensor array) to search for
nine point mutations in codons 248, 249 and 273 of the
TP53 gene.
Results
PCR products and reference hybridization patterns
PCR products from exon 7 (codons 248 and 249) and
exon 8 (codon 273) were obtained from each type of DNA
sources listed in Materials and Methods. Figure 2A shows
gel electrophoretic analysis of the fragments of 108 and 92
bp corresponding to exons 7 and 8, respectively. To pre-
pare ssDNA targets PCR products were used as templates
for cycle synthesis of a target strand, using the reverse PCR
primer in single or multiplexed reactions cycled 25 times.
The production of single-stranded target DNA's was
assessed by its change in electrophoretic mobility in 4%
agarose gels (Figure 2B).
The reference hybridization patterns produced using syn-
thetic DNA targets are shown in Figures. 3A and 3B. As
expected, all the synthetic targets, including those of the
negative controls, yielded hybridization signals with their
respective ("perfect-match") probes. Pairs of wild-type
with each mutant synthetic target sequences (1:1 mix-
tures) were also hybridized to reproduce heterozygous
conditions. All gave the expected signals, (Figure 3B).
Hybridization of DNA targets
Hybridization of individual or multiplexed ssDNA targets
prepared from the 24 DNA samples (that correspond to
72 codons in 24 samples) was performed with similar
results. Base substitutions were seen in 11 out of the 24
samples tested (Table 3). One, two or three codons were
altered in 5 (P6, L1, L2, B3 and B6), 5 (P1, L4, L7, L9 and
L10) and 1 (L8) samples, respectively. In the cases of the
samples having two or three codons affected, at least one
of the base substitutions was silent. In the other 13 sam-
ples only WT sequences were identified (data not shown).
Representative hybridization patterns are shown in Fig-
ure. 4A and the overall results are summarized in Table 3.
The DNA samples hybridized with one or two probesBMC Biotechnology 2005, 5:8 http://www.biomedcentral.com/1472-6750/5/8
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from each codon, corresponding to the homozygous or
heterozygous condition, respectively. Among the 24 dif-
ferent samples multiplexed or individually tested in the
microarray, six single base susbstitutions in codon 248
were found by sequencing the PCR product. All of them
corresponded to base substitutions keeping the original
aminoacid (Arginine). The same number of point muta-
tions were also seen in codon 249 by DNA sequencing.
However, no probes to search for these base substitutions
were placed in the DNA microarray. Six point mutations
in codon 273 were obtained. All of them, except the
CGT→CCT change observed in plasmid P6, were searched
with the set of probes contained in the DNA microarray.
In this codon all the base substitutions are producers of
aminoacid substitution.
Discussion
The TP53 tumor suppressor gene has proven to be one of
the cellular genes most often mutated in human neopla-
sias. Analysis of the mutational events that target the TP53
gene has revealed evidence for both exogenous and
endogenous mutational mechanisms. This gene muta-
tional spectrum suggests evidence for a direct causal effect
of tobacco smoke in lung cancer [26,27], aflatoxin B1 in
liver cancer [28]. Therefore, identification of mutations in
the TP53 gene may play an important role in the diagno-
sis, staging, and management of the cancer patients.
More than 70% of the molecular studies have focused on
the central region of the TP53 gene, more specifically on
exons 5 through 8 which encode the DNA binding
domain [3]. Thus, missense mutations in this region can
cause a modification that may alter DNA binding. It is
therefore essential that clinical trials aim to accurately
establish the effect of TP53  mutations on all clinical
parameters. One approach is the p53 GeneChip of
Affymetrix used to identify mutations in this gene [13,14].
However, this technology is expensive and poorly availa-
ble to many clinicians, which makes it necessary to
develop new mutation detection methods [29,30].
The updated IARC TP53 mutation database [38] shows
that more than 1700 different point mutations, which are
associated to cancers, are distributed along the TP53 gene.
TP53 somatic mutations are found in most types of spo-
radic human cancers at various frequencies (from 20% to
60%) [13,14]. The database also shows that approxi-
mately 20% of all mutations are located in the five codons
(hotspots) in the core domain: 175, 245, 248, 249 and
273. Therefore a primary screen of these codons would be
attractive.
Most SNP diagnostic arrays use probes varying from 15 to
20 nt in length with similar Tm values [31]. However,
under this circumstance some of the mutant sequences are
difficult to discriminate, due to the relatively small desta-
bilizing effect of certain single mismatches in the probe/
target duplex [32].
The tandem hybridization method described here offers
several advantages over the traditional oligonucleotide
array configuration in which each interrogated target
sequence is represented by a single surface-tethered probe.
Because the long stacking probe targets the analysis to a
single unique site within a nucleic acid, direct hybridiza-
tion analysis of nucleic acid samples of high genetic com-
plexity using short capture probes may be enabled [24].
Recently, we successfully used a double tandem hybridi-
zation strategy in the genesensor chip system to discrimi-
nate point mutations in codon 634 of RET oncogene in
individuals affected by medullary thyroid carcinoma [23].
This DNA chip format involves a target sequence which is
annealed with a pair of labeled oligonucleotides (stabiliz-
ing oligonucleotides) prior to hybridization to the array of
capture probes, forming a single-stranded gap between
Electrophoretic analysis of PCR products and single-stranded  target DNA produced by "cycle sequencing" Figure 2
Electrophoretic analysis of PCR products and single-
stranded target DNA produced by "cycle sequenc-
ing." (A): Electrophoresis in 2% agarose gel from PCR reac-
tions of regions from exons 7 and 8 of the TP53 gene: 100 bp 
ladder (Lane 1), 108 bp PCR product from exon 7 (lane 2), 
92 bp PCR product from exon 8 (lane 3). (B): Electrophore-
sis in 4% agarose gel of two multiplex PCR reactions from 
exons 7 and 8 of the TP53 gene. Lanes 1 and 3 represent the 
products of two different samples; lane 2 is the 100 bp 
ladder.
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Hybridization of synthetic targets Figure 3
Hybridization of synthetic targets. (A) Homozygous pattern. Hybridization pattern produced by synthetic target (ST) on 
probes (arrayed onto 14 slides). Synthetic targets were annealed with prelabeled stacking oligonucleotides and hybridized with 
the array of probes having sequence variations. (B) Heterozygous pattern. Hybridization patterns produced by heterozygous 
combination of synthetic targets (ST) on probes. Equivalent amounts of wild type and mutant synthetic targets were annealed 
with prelabeled 5'and 3'stacking oligonucleotides, then hybridized with the array of probes having sequence variations (see 
Table 1).
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the stabilizing oligonucleotides and corresponding to the
length of the capture probes. The partially duplex product
contains the sequences interrogated by the capture
probes, and when the sequences between the target DNA
and the capture probe (attached to slide) are perfectly
complementary, the stability of the hybridization is
enhanced due to coaxial stacking of bases between the
contiguous ends of the probe and the stabilizing oligonu-
cleotides. The energy involved varies with the identity of
the base pairs and the coaxial stacking [22]. Tandem
hybridization uses shorter capture probes than traditional
oligonucleotide array hybridization, which may contrib-
Table 3: Detection of TP53 silent and missense base substitutions using DNA sequencing versus DNA microarray hybridization.
ID Genotype Mutation
DNA sequencing Results of hybridization
P1 Pp53 248 wtCGG→mutCGC No wild type signal: mutant probe absent Silent
249 wtAGG→mutAGA No wild type signal: p-249 G2→T Silent
273 wtCGT p-273 WT Silent
P6 cDNA 248 wtCGG p-248 WT Silent
249 wtAGG p-249 WT Silent
273 wtCGT→mutCCT No wild type signal: mutant probe absent Proline
L1 A-427 248 wtCGG→mutCGT p-248 WT: mutant probe absent Silent
249 wtAGG p-249 WT Silent
273 wtCGT p-273 WT Silent
L2 C33 A 248 wtCGG p-248 WT Silent
249 wtAGG p-249 WT Silent
273 wtCGT→mutTGT p-273 C→T Cysteine
L4 Jurkat 248 wtCGG→mutCGK* p-248 WT: mutant probe absent Silent
249 wtAGG→mutAGR** p-249 G2→T: mutant probe absent p-249 WT Silent
273 wtCGT p-273 WT Silent
L7 SW480 248 wtCGG p-248 WT Silent
249 wtAGG→mutAGR** p-249 G2→T: mutant probe absent p-249 WT Silent
273 wtCGT→mutCAT p-273 G→AH i s t i d i n e
L8 I-37 248 wtCGG→mutCGC No wild type signal: mutant probe absent Silent
249 wtAGG→mutCGA No wild type signal: mutant probe absent Silent
273 wtCGT→mutTGT p-273 C→T Cysteine
L9 I-51 248 wtCGG→mutCGC No wild type signal: mutant probe absent Silent
249 wtAGG→mutCGA No wild type signal: mutant probe absent Silent
273 wtCGT p-273 WT Silent
L10 PCS-4 248 wtCGG→mutCGC No wild type signal: mutant probe absent Silent
249 wtAGG→mutCGA No wild type signal: mutant probe absent Silent
273 wtCGT p-273 WT Silent
B3 Case 116 248 wtCGG p-248 WT Silent
249 wtAGG p-249 WT Silent
273 wtCGT→mutCTT p-273 G→T Leucine
B6 Case 152 248 wtCGG p-248 WT Silent
249 wtAGG p-249 WT Silent
273 wtCGT→mutCTT p-273 G→T Leucine
*K = G or T (Heterozygous), **R = G or A (Heterozygous)BMC Biotechnology 2005, 5:8 http://www.biomedcentral.com/1472-6750/5/8
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ute to increased discrimination of point mutations
because the single base mismatch acts on a less stable
duplex formed between the target DNA and the shorter
probe. Two additional attractive features inherent to tan-
dem hybridization are that, i) the probability that
formation of secondary structure within the single
stranded DNA [25] will block accessibility of the target
sequence is reduced, and ii) the label needed to reveal the
hybridization can be introduced into the two stabilizing
oligonucleotides, avoiding the extra step of labeling indi-
vidual target strands [33,34].
The goal of the present work was to develop a simple for-
mat array able to perform a primary screening of the
mutations occurring in the most frequently affected
codons of the TP53 gene.
It has been recently reported that detection of mutations
yields variable results depending on the type of DNA sam-
ple [35,36]. Is clear that, the sensitivity to detect muta-
tions in TP53, may also differ depending on the method
used. In the current study the double tandem hybridiza-
tion assay was applied to genomic DNA samples extracted
Hybridization of samples proposed in the multiplex format Figure 4
Hybridization of samples proposed in the multiplex format. (A). Sample with wild type genotype. Representative 
experiment of multiplex hybridization assay with sample P1. The red arrows indicates the wild type hybridization signals. The 
DNA obtained was individually annealed with the two pairs of stacking oligonucleotides and hybridized in one assay. Above 
Multiplex Assay with sample L7. The hybridized with their respective array of probes having sequence variations. The DNA 
obtained was annealed the two pairs of stacking oligonucleotides and hybridized in the multiplex format with. (B) The electro-
pherogram showed the sequence wild type of the interest codon. The pink row pointed the signal of the probe in the microar-
ray (point mutation).
Sample L7: Mutant Exon 7. Antisense strand.
Sample B1: WT Exon 8. Antisense strand.
Sample L7: Mutant Exon 8. Antisense strand.
Sample B1: WT Exon 7. Antisense strand.
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from a variety of sources, including blood cells, cell lines
and plasmids. There were not any differences in the ability
of our system to detect mutations with respect to the dif-
ferent DNA sources.
In the experiments employing synthetic DNA targets
hybridized with arrays of mutant and WT probes the
expected hybridization signals were seen both in
homozygous and heterozygous conditions (Figure. 3).
This result indicates that the probes are working properly.
The hybridization of natural targets was done both with
isolated and multiplexed PCR products with similar
results. Multiplexing was applied in all (PCR reaction
ssDNA target preparation, annealing of target with stack-
ing oligonucleotides and hybridization) the steps. So
these results are suggesting that multiplexing can be con-
fidently employed for this analysis.
Base changes were found in 11 DNA samples. Two were
from plasmid, seven from cell lines and two from blood
samples. In 5 of these samples a single codon was affected,
in other 5 samples two codons were altered, and in the
other sample three codons were affected. Therefore a total
of 18 codon alterations were detected. In five of the 18
codon alterations (Samples L2 codon 273, L7 codon 273,
L8 codon 273, B3 codon 273 and B6 codon 273) both the
absence of hybridization signal with the wild type probe
and the production of signal with the appropriated probe
was seen. In eight cases (Samples P1 codon 248, P6 codon
273, L8 codons 248 and 249, L9 L8 codons 248 and 249
and L8 codons 248 and 249 and, L10 codons 248 and
249) no hybridization signal was seen even with the wild
type sequence. This was due to the absence of the corre-
sponding mutant probe in the array. In three cases (P1
codon 249, L4 codon 249 and L7 codon 249) having
either homozygous (sample P1) or heterozygous (sam-
ples L4 and L7) genotypes (wtAGG→mutAGA) no hybrid-
ization signal with the wild type probe and, an additional
false hybridization signal with the probe corresponding to
the substitution of guanine for thymine in codon 249 (p-
249 G2→T) was seen, which could be relatively stable
under the conditions tested. Therefore an additional
probe, searching by the AGA sequence, should be added
in the future array to discriminate between the two alter-
native silent (AGA) and missense (AGT) genotypes. In the
other two codons affected (L1 codon 248 and L4 codon
248) the presence of signal with the wild type probe was
seen even when the sequencing was showing a base
change (wtCGG→mutCGT in sample L1 or 248 wtCG-
G→mutCGK in sample L4). In both cases a G:N mismatch
is formed which, according to SantaLucia [37], is rela-
tively stable. So, as in the previous two cases the incorpo-
ration of additional probes in the array should help to
improve performance of the DNA microarray to confi-
dently identify the genotypes.
The base substitution observed in B3 and B6 blood sam-
ples is a mutation that substitutes Arginine by Leucine.
The presence of this mutation in blood suggests that it
could be from germinal origin.
In all the mutations (silent and missense) observed an
Arginine was involved, which can be expected because it
is coded by 6 codons and it frequently produces non con-
servative aminoacid substitutions.
The array is able to confidently detect most of the muta-
tions searched, however, additional probes should be
added to improve its performance.
Conclusions
Our results demonstrate that a simple TP53 microarray
using short (7-mer) probes, used in combination with a
double tandem hybridization approach and a simple
multiplex fragment preparation method, can identify
common  TP53  point mutations from different DNA
sources. All the previous data confirms that the tandem
hybridization technology, with the appropriated set of
probes, is highly specific and can be confidently
employed for diagnostic purposes. This system could pro-
vide rapid, economical and accurate mutational screening
in the TP53 gene. We are presently improving our system
by adding probes for these and other TP53 mutational hot
spots.
Methods
IARC TP53 gene database search
The distribution of nucleotidic changes in the TP53 gene
associated with all cancers war retrieved from the IARC
TP53 database [38]. Then, the single base substitutions
occurring in the 3 exons of TP53 most frequently altered
in cancers were obtained. Both wild type (accession #
U94788) and mutated TP53  sequences were used to
design the probes, stacking oligonucleotides, PCR primers
and synthetic targets.
Oligonucleotides
Four new PCR primers of 20–25 nt length (Table 1) were
used to amplify two DNA fragments of 108 bp (exon 7:
codons 248 and 249) and 92 bp (exon 8: codon 273)
within the TP53 gene. Six stacking oligonucleotides of 17–
21 nt length were annealed with their corresponding tar-
get DNA's, in three pairs, to produce partially duplex
DNA's having a 7-nt gap which is the sequence interro-
gated by the capture probes (Figure 1A). Fourteen capture
probes (seven-mer length; Table 1) were designed, two of
them to search the wild type sequences for codons 157
and 158, which were used as negative controls, three moreBMC Biotechnology 2005, 5:8 http://www.biomedcentral.com/1472-6750/5/8
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for the wild type 248, 249 and 273 codon sequences and
nine to look for mutant sequences. According to our pre-
vious experience, 7-mer oligonucleotides with base
changes located at central positions were selected as
probes in order to yield good discrimination of point
mutations by tandem hybridization at room temperature.
The probes, which had a 3'-aminolink (3'-aminopropa-
nol) modification for covalent binding to the glass slide
surface [24], were purchased from Integrated DNA Tech-
nologies Inc. (Coralville, IA, USA).
Biological samples (DNA targets)
Twenty-four DNA samples from different sources were
probed, some having known wild type or mutant TP53
sequences and others with unknown TP53  genotype.
These included eight blood samples (B), two obtained
Table 1: Primers, stacking oligonucleotides, synthetic targets and capture probes used.
Primers
Name Sequence (5'→3')
PCREX7-F GCTCTGACTGTACCACCATCCA
PCREX7-R ACCTGGAGTCTTCCAGTGTGA
PCREX8-F ACTGGGACGGAACAGCTTTGA
PCREX8-R GCTCCCCTTTCTTGCGGAGAT
Stacking oligonucleotides
Name Sequence (5'→3')
LSO108–248 CCTGCATGGGCGGCATG
RSO108–248 GGCCCATCCTCACCATCATC
LSO108–249 GCATGGGCGGCATGAACCG
RSO108–249 ATCCTCACCATCATCACTC
LSO92–273 GGGACGGAACAGCTTTGAGG
RSO92–273 TTGTGCCTGTCCTGGGAGA
Synthetic targets
Name Sequence (5'→3')
ST-157,158WT GGTGTGGGGGCGGGCCGTGGGCGCAGGCGCGGTACCGGTAGATGTTCGTC
ST-248,249WT GTGTGATGATGGTGAGGATGGGCCTCCGGTTCATGCCGCCCATGCAGG
ST-248C→T GATGATGGTGAGGATGGGCCTCCAGGTCATGCCGCCCATGCAGG
ST-248G1→T GATGATGGTGAGGATGGGCCTCAGGTTCATGCCGCCCATGCAGG
ST-248G1→A GATGATGGTGAGGATGGGCCTCTGGTTCATGCCGCCCATGCAGG
ST-249G1→T TGATGATGGTGAGGATGGGCATCCAGTTCATGCCGCCCATGCAGG
ST-249G2→T TGATGATGGTGAGGATGGGACTCAGGTTCATGCCGCCCATGCAGG
ST-249G2→C TGATGATGGTGAGGATGGGGCTCTGGTTCATGCCGCCCATGCAGG
ST-273WT CTCTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCC
ST-273G→T CTCTCCCAGGACAGGCACAAACAAGCACCTCAAAGCTGTTCCGTCCC
ST-273G→A CTCTCCCAGGACAGGCACAAACATGCACCTCAAAGCTGTTCCGTCCC
ST-273C→T CTCTCCCAGGACAGGCACAAACACACACCTCAAAGCTGTTCCGTCCC
Capture probes
Name Sequence (5'→3')
p-157WT CGCGTCC@
p-158WT GTCCGCG@
p-248WT AACCGGA@
p-248C→TA A C T G G A @
p-248G1→T AACCTGA@
p-248G1→A AACCAGA@
p-249WT GAGGCCC@
P-249G1→T GATGCCC@
P-249G2→T GAGTCCC@
P-249G2→C GAGCCCC@
P-273WT = TGCGTGT@
P-273-G→T TGCTTGT@
P-273G→A TGCATGT@
P-273C→T TGTGTGT@
@ = 3'-aminopropanol modification for glass attachment.
Base changes are represented in boldBMC Biotechnology 2005, 5:8 http://www.biomedcentral.com/1472-6750/5/8
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Layout of the TP53 low density DNA microarray Figure 1
Layout of the TP53 low density DNA microarray. (A): Names and alignment of stacking oligonucleotides and probes to 
their respective synthetic wild type target sequence. Bold letters correspond to the nucleotide change in DNA sequence due 
to the point mutations. (B): Layout of the probe array on the glass slide. The probes were applied to the slide in triplicate as 
depicted at the top. The numbers correspond to the probes in Table 1.
  Synthetic targets with           Codon 249 
  Wild type and         TGATGATGGTGAGGATGGGGCTCTGGTTCATGCCGCCCATGCAGG (T-249 G2→C) 
  different point       TGATGATGGTGAGGATGGGACTCAGGTTCATGCCGCCCATGCAGG (T-249 G2→T)
  mutations             TGATGATGGTGAGGATGGGCATCCAGTTCATGCCGCCCATGCAGG (T-249 G1→T)
                         GATGATGGTGAGGATGGGCCTCTGGTTCATGCCGCCCATGCAGG (T-248 G→A)
                         GATGATGGTGAGGATGGGCCTCAGGTTCATGCCGCCCATGCAGG (T-248 G→T) 
                         GATGATGGTGAGGATGGGCCTCCAGTTCATGCCGCCCATGCAGG (T-248 C→T) 
                     GTGTGATGATGGTGAGGATGGGCCTCCGGTTCATGCCGCCCATGCAGG (T-248 WT)
              (SO-248 R) CTACTACCACTCCTACCCGG       GTACGGCGGGTACGTCC (SO-248 L)
          (SO-249 R) CTCACTACTACCACTCCTA       GCCAAGTACGGCGGGTACG (SO-249 L)
                                            @AGGCCAA (p-248 WT)
    Stacking oligonucleotides               @AGGTCAA (p-248 G→T)         Stacking 
                                            @AGTCCAA (p-248 G→T) oligonucleotides
                                            @AGACCAA (p-248 G→A) 
            Capture probes             @CCCGGAG (p-249 WT) 
                                       @CCCGTAG (p-249 G1→T) 
                                       @CCCTGAG (p-249 G2→T) 
                                       @CCCCGAG (p-249 G2→C) 
 
                                   Codon 273
  Wild type and      CTCTCCCAGGACAGGCACAAACACACACCTCAAAGCTGTTCCGTCCC (T-273 C→T)
  Different point    CTCTCCCAGGACAGGCACAAACATGCACCTCAAAGCTGTTCCGTCCC (T-273 G→A) 
  mutations          CTCTCCCAGGACAGGCACAAACAAGCACCTCAAAGCTGTTCCGTCCC (T-273 G→T) 
                     CTCTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCC (T-273 WT)
          (SO-273 R) GAGAGGGTCCTGTCCGTGTT       GGAGTTTCGACAAGGCAGGG (SO-273 L)
                                        @TGTGCGT (p-273 WT)  
  Stacking oligonucleotide              @TGTTCGT (p-273 G→T)             Stacking 
                                        @TGTACGT (p-273 G→A)      oligonucleotide
           Capture probes               @TGTGTGT (p-273 C→T) 
  
 
A
     
  12 12 12 12      12 12 12 12 12 12 12 12     
 13  13  13  13     13 13 13 13 13 13 13 13     
14 14 14 14 14 14 14 14  14  14  14  14     
11 11 11 11
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13 13 13 13
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B
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from healthy subjects and six obtained from lung cancer
affected patients, and ten established cancer cell lines or
recombinant DNA's acquired from the ATCC (L). Two of
the cell lines were a generous gift from Dr Mary A Salazar
(IIB, UNAM) and one was a gift from Dr José Sullivan
(INER, SS, Mexico). The other eight cell lines were pro-
vided by the DNA bank from Genomic Oncology Labora-
tory (CMN S XXI). Finally, six recombinant plasmids (P)
harboring TP53 (wild type or different point mutations),
provided by MSc. Irene Correa (CMN S XXI) were
employed to standardize the hybridization arrays. The
names, identification numbers, source and known geno-
types in the 24 samples studied are described in Table 2
Target preparation and PCR assay
Genomic DNA was isolated and purified using the
Genomic DNA Extraction Kit (Life Technologies Inc.,
Gaithersburg, MD). DNA concentration was determined
by absorbance at 260 nm in a spectrophotometer MBA
2000 (Perkin-Elmer) and by the PicoGreen®  dsDNA
Quantitation Kit (Molecular Probes).
Plasmid DNA was prepared from bacterial cultures using
the alkaline lysis/SDS minipreparation according to the
manufacturer's instructions (Life Technologies).
The quality of the DNA preparations was assessed by gel
electrophoresis in 1% agarose. All the reagents for PCR
reactions were purchased from Promega (Madison WI.
USA). The PCR primers are described in Table 1. Oligonu-
cleotides sequences and fragment sizes for each exon were
as follows: PCREX7-F and PCREX7-R for a 108 bp product
in exon 7, and PCREX8-F and PCREX8-R for a 92 bp frag-
ment in exon 8. The final reaction mixture contained 0.2
mM each dNTP, 50 mM KCl, 10 mM Tris-HCl (pH 8.4),
1.5 mM MgCl2, 0.5 µM each primer, 2.5 U of Taq DNA pol
(Promega) and purified DNA (50–100 ng) in a final vol-
ume of 100 µL. The PCR profile consisted of an initial
heating at 94°C for 5 min, followed by 30 cycles of 94°C
for 30 s, 55°C for 30 s and 72°C for 30 s, with a final
extension step at 72°C for 7 min. The PCR product was
assessed by electrophoresis in 1 % agarose gel stained with
ethidium bromide.
Single-stranded target DNA was prepared by cycle synthe-
sis as follows. A 30-µL aliquot of PCR product was
Table 2: Biological samples tested.
ID Name Source The genotype was previously 
assumed as:
P1 pp53 Plasmid Unknown
P2 pSCX3 Plasmid Unknown
P3 pM47 Plasmid Unknown
P4 pC53 Plasmid Unknown
P5 XbaI Plasmid Unknown
P6 C1 Plasmid Unknown
L1 A-427 Human cell line Unknown
L2 C33 A Human cell line Point mutation in codon 273
L3 Hela Human cell line Unknown
L4 Jurkat Human cell line Heterozygous for p53 ***
L5 SiHa Human cell line Unknown
L6 T24 Human cell line Unknown
L7 SW480 Human cell line Unknown
L8 I-37 Human lung tumor sample Unknown
L9 I-51 Human lung tumor sample Unknown
L10 PCS-4 Human lung tumor sample Unknown
B1 Case 1 PBLCA Unknown
B2 Case 2 PBLCA Unknown
B3 Case 116 PBLCA Unknown
B4 Case 4 PBLCA Unknown
B5 Case 5 PBLCA Unknown
B6 Case 152 PBLCA Unknown
B7 Case 7 PBHS Unknown
B8 Case 8 PBHS Unknown
*PBLCA = Peripheral blood lung cancer affected.
**PBHS = Peripheral blood healthy subject.
***Personal communication.BMC Biotechnology 2005, 5:8 http://www.biomedcentral.com/1472-6750/5/8
Page 11 of 13
(page number not for citation purposes)
processed using Ultrafree (Millipore, Bedford, MA) spin
filters (30,000 Mr cutoff), and resuspended in the same
volume of HPLC-grade water (OMNI SOLV®, EM Science).
A 5-µL aliquot of this solution was added to a 100-µL PCR
reaction, along with the primer corresponding to the tar-
get strand, then incubated for 27 temperature cycles using
the same temperature profiles described above. The for-
mation of each amplicon was assessed by mobility shift in
agarose gel electrophoresis.
Each one of the six stacking oligonucleotides was 5'-
labeled by reaction with T4 polynucleotide kinase (Invit-
rogen, San Diego, CA) as follows. 5 pmol of each
dephosphorylated stacking oligonucleotide; 5X Forward
Reaction Buffer (5 µl); T4 Polynucleotide Kinase (10
unit); [γ32P]ATP (10 µCi/µl, 3000 Ci/mmol) 2.5 µl (NEN,
Boston MA), specific activity 7000 Ci/mmol, diluted in
sterile water to 7 µCi/µl, and autoclaved water HPLC-
grade to 25 µl. The mix was incubated 10 min at 37°C and
the reaction was stopped by adding 5 mM EDTA (2.5 µl).
To prepare labeled partially duplex (gapped) target
DNA's, each pair of γ32P-labeled stacking oligonucleotides
was preannealed with the respective synthetic DNA target,
single-stranded PCR fragments or multiplexed, single-
stranded PCR products to form a 7-nt gap in each target.
The annealing mixture contained 50 µL 20X SSC, 10 µL 1
M Tris-HCl (pH 8.0), 3 µL 0.5 M EDTA, 0.2 pmol of each
labeled stacking oligonucleotide, 10 µL of target DNA,
and HPLC-grade H2O to a final volume of 90 µL. The mix-
ture was incubated at 95°C for 5 min, 45°C for 5 min,
then 6°C for 5 min. Excess [γ32P]ATP was removed by fil-
tration through an Ultrafree spin filter (3,000 Mr cutoff)
(Millipore. Bedford, MA), and the retained DNA was dis-
solved in 20 µL of 1X SSC.
In the case of multiplexed targets, only 4 stacking oligonu-
cleotides (SO-248-R, SO-249-L, SO-273R and SO-273-L)
were added, one pair for each exon in the study, forming
gap sizes of 12 and 7 nt for exons 7 and 8, respectively.
Thus, with exon 7 a single tandem hybridization was con-
ducted with the glass-tethered 7-mer capture probes,
whereas with exon 8 double tandem hybridization was
conducted.
DNA probe arrays
Glass microscope slides were prepared by soaking in hex-
ane 20 min, then 20 min in absolute ethanol followed by
drying 5 h at 90°C. Oligonucleotide probes containing 3'-
terminal aminopropanol modification were dissolved in
sterile water to a final concentration of 20 µM, and 200 µl
droplets of each probe were applied to the glass slides
using a model 417 Affymetrix (Santa Clara, CA) arrayer to
place submicroliter droplets onto glass slides. Each array
contained 14 probes: three wild type sequences and nine
mutant sequences corresponding to the TP53  targets
under study, two negative controls consisting of 7-mers
targeted to the wild type sequences from codons 157 and
158 of TP53 gene, plus one blank spot without probe. As
depicted in Fig. 1B, each TP53 capture probe was arrayed
in triplicate (to assess the reproducibility of the results) in
an upward direction starting from position 1 and the
printing was divided into three groups. Positions 1–14
were printed first, then the pattern was repeated twice
more across the slide. Position 15 was left empty (nothing
at all was applied) and served as a negative glass control.
After spotting, each slide was washed with water to
remove unbound oligonucleotides, air-dried, then stored
in a dessicator at room temperature. This attachment pro-
cedure results in a surface density of 1010-1011 molecules
mm2, which corresponds to intermolecular spacing of
about 30–100 Å across the surface [25].
Hybridization experiments
Just prior to hybridization the slides were soaked for 1 h
at room temperature with blocking agent (10 mM
tripolyphosphate) and then rinsed twice with water and
air-dried. The hybridization cocktail contained: 118 µL 5
M tetramethyl-ammonium chloride (TMAC) (Life Tech-
nologies), 9 µL 1 M Tris-HCl (pH 8.0) (Life Technologies),
0.72 µL 0.5 M EDTA, 1.8 µL 10% (w/v) sodium dodecyl
sulfate, 14.4 µL 40% (w/v) polyethylene glycol, 20 µL
labeled target DNA in 1X SSC, and 35.3 µL HPLC-grade
water. A 40-µL aliquot of this cocktail was placed onto
each array and a cover slip was applied. Slides were incu-
bated in a humid chamber for 3 h at 25°C. After hybridi-
zation, the slides were washed by dipping several times in
the same hybridization solution without polyethylene
glycol and DNA, air-dried, and then wrapped in plastic
film and placed against X-ray film (Kodak BioMax) for
autoradiography. Detection and quantitation of 32P-
labeled target molecules bound across the hybridization
array was performed with a scanner (HP Scanjet 4400 c),
and analysis of densitometric images was performed using
ScanAnalyze 2 software (Stanford University).
To provide confidence in the interpretation of the signals
produced by human samples, reference hybridization pat-
terns were prepared using a full set of synthetic targets. For
this purpose, thirteen synthetic targets (44–50 nt), repre-
senting the wild type and mutant sequences, were used
independently and in combination, to represent
homozygous and heterozygous conditions.
Sequencing of PCR products
The PCR products obtained were purified using the
QIAEX II kit (QIAGEN Inc. USA). For each PCR product
the presence or absence of a mutation in exons 7 and 8
was demonstrated via sequencing using the Big Dye Ter-
minator kit (Perkin-Elmer) and a model 373 automatedBMC Biotechnology 2005, 5:8 http://www.biomedcentral.com/1472-6750/5/8
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DNA sequencer (Instruments Core Center of Health
Research Council- IMSS).
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